Last reviewed · How we verify
Malignant epithelial tumor of ovary
Approved treatments
- Avastin · Washington University School of Medicine
- Zejula · GSK
Zejula works by blocking the action of an enzyme called PARP, which helps repair damaged DNA in cancer cells. - Bevacizumab · Roche
Bevacizumab binds VEGF and prevents interaction with endothelial cell receptors Flt-1 and KDR. - Vynfinit
Vynfinit works by binding to folate receptor beta, which is overexpressed in certain cancer cells, and delivering a toxic payload to these cells. - Avastin · Roche
Bevacizumab works by binding to VEGF-A, preventing it from promoting the growth of new blood vessels that feed tumors.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Malignant epithelial tumor of ovary patent landscape — cliff calendar, originator estates, attackable patents
- Malignant epithelial tumor of ovary treatment landscape brief
- Malignant epithelial tumor of ovary treatment updates RSS
Frequently asked questions about Malignant epithelial tumor of ovary
What drugs treat Malignant epithelial tumor of ovary?
Tracked treatments include Avastin, Zejula, Bevacizumab, Vynfinit.
What is the treatment for Malignant epithelial tumor of ovary?
Standard treatment for Malignant epithelial tumor of ovary includes Avastin, Zejula, Bevacizumab, Vynfinit. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Malignant epithelial tumor of ovary patent cliff · Malignant epithelial tumor of ovary CI report
- Treatment: Avastin · Washington University School of Medicine
- Treatment: Zejula · GSK
- Treatment: Bevacizumab · Roche
- Treatment: Vynfinit
- Treatment: Avastin · Roche
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing